A RCT compared eptinezumab (a new CGRP antagonist) to topira…
A RCT compared eptinezumab (a new CGRP antagonist) to topiramate for migraine prevention using an NI margin of 0.5 monthly migraine days. The mean decrease in monthly migraine days with eptinesumab was 3.9 days and with topiramate was 4.1 days (mean difference 0.2 days; 95%CI -0.02 to 0.42). Which of the following statements is the best interpretation of the results?
Read Details